Autoimmune polyendocrine syndrome type I (APS-I), also known as autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy (Online Mendelian Inheritance in Man no. 240300), is a rare, autosomal recessive primary immunodeficiency first described clinically in 1929 ([@bib33]; [@bib15]). APS-I is characterized principally by multiple autoimmune endocrinopathies, hypoparathyroidism, and adrenal insufficiency in particular, with some of these symptoms being caused by pathogenic autoantibodies (auto-Abs). A genome-wide mapping approach led to the identification of APS-I--causing mutations in the *AIRE* gene in 1997 ([@bib10]; [@bib31]). Autoimmunity in patients with APS-I may be accounted for by the key role of *AIRE* in tolerance. *AIRE* is expressed in the thymus, where it contributes to the expression of peripheral antigens ([@bib2]; [@bib24]). This gene has also been shown to be expressed in secondary lymphoid organs, where it also contributes to tolerance ([@bib12]). Surprisingly, most patients with APS-I suffer from chronic mucocutaneous candidiasis (CMC) without displaying any marked susceptibility to any other pathogen. The product of the *AIRE* gene is not involved in any known cellular pathway governing host defense. The pathogenesis of CMC in patients with APS-I has thus remained both intriguing and elusive.

High titers of auto-Abs against some type I IFNs, including IFN-α and -ω in particular, are found in all patients ([@bib25]; [@bib26]). These auto-Abs are a hallmark of APS-I and are therefore useful for diagnostic purposes ([@bib15]). However, they confer no particular overt predisposition to viral diseases, perhaps because of the large number of redundant type I IFN species, resulting in incomplete neutralization of the overall antiviral activity of IFNs by the auto-Abs. It has been suggested that these auto-Abs contribute to CMC in APS-I patients ([@bib25]). However, this is now thought unlikely because of the absence of CMC in patients with various forms of STAT1 and TYK2 deficiency and impaired responses to type I IFNs, and in patients with various forms of NEMO, UNC-93B, and TLR3 deficiencies and impaired production of type I IFNs ([@bib28]; [@bib40]; [@bib3]). Nevertheless, based on this observation, we hypothesized that CMC in patients with APS-I might result from autoimmunity to cytokines other than type I IFNs potentially involved in protective immunity to *Candida albicans* in the skin and mucosae.

Recent studies in the mouse have suggested that IL-17 cytokines, such as IL-17A, IL-17F, and IL-22 ([@bib19]), may be important in host defense against *Candida* ([@bib4]; [@bib39]). However, it is difficult to assess mucocutaneous immunity to *Candida* in mice ([@bib32]), in which IL-17 cytokines seem to be important for the control of various other pathogens, particularly in the lungs and gastrointestinal tract ([@bib7]; [@bib17]). Stimulation with *Candida* in vitro leads to the preferential generation of IL-17A-- and IL-22--producing human T cells ([@bib1]; [@bib21]). Furthermore, patients with STAT3 deficiency display a predisposition to CMC (and staphylococcal disease) and lack IL-17--producing T cells ([@bib5]; [@bib22]; [@bib27]; [@bib30]). Similarly, some patients with IL-12p40 or IL-12Rβ1 deficiency present CMC (together with mycobacteriosis and salmonellosis) and have lower than normal proportions of IL-17--producing T cells ([@bib5]). Finally, patients with rare defects of CARD9, which normally controls the production of IL-17 in response to dectin-1 and -2 stimulation by *Candida*, suffer from candidiasis ([@bib20]; [@bib13]; [@bib36]). We therefore hypothesized that autoimmunity to IL-17 cytokines might account for CMC in patients with APS-I.

RESULTS AND DISCUSSION
======================

We searched for auto-Abs against IL-17 cytokines (IL-17A, IL-17F, IL-22, and IL-26, which is absent from mice) or against IL-17--inducing cytokines (IL-1β, IL-6, IL-21, IL-23, and TGF-β) in 33 patients diagnosed with APS-I on the basis of autoimmune polyendocrinopathy, circulating auto-Abs against IFN-α and --ω, and the presence of two mutant *AIRE* alleles ([Table I](#tbl1){ref-type="table"}). CMC was observed in 29 out of the 33 patients ([Table I](#tbl1){ref-type="table"}). Multiplex particle-based flow cytometry revealed a high fluorescence intensity (FI; \>1,000, arbitrary definition) of IgG auto-Abs against IL-17A in the plasma of 22 patients, with a high FI of auto-Abs against IL-17F in 31 patients and of auto-Abs against IL-22 in 30 patients ([Fig. 1](#fig1){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}). All 33 patients had significant (P = 6.4 × 10^−9^, 4.6 × 10^−12^, and 2.16 × 10^−11^, respectively) levels of auto-Abs against at least one of these three cytokines. 5 patients had a significant reaction against a single cytokine, 6 had a reaction against two cytokines, and 22 had a reaction against all three cytokines. No auto-Abs against IL-17A, IL-17F, and IL-22 were found in plasma samples from the 37 healthy individuals tested. Similarly, no auto-Abs against any of these three cytokines were found in plasma samples from another 103 patients with various autoimmune conditions ([Fig. S4, A and B](http://www.jem.org/cgi/content/full/jem.20091983/DC1)). No auto-Abs against IL-1β, IL-6, IL-23, or IL-26 (whether as a monomer or a dimer) were found in the APS-I patients ([Fig. S3, A--D](http://www.jem.org/cgi/content/full/jem.20091983/DC1)). There were no auto-Abs against IL-12, IFN-γ, or GM-CSF (Fig. S3, E--G), consistent with the lack of mycobacterial disease and alveolar proteinosis in patients with APS-I. No auto-Abs were found against any of the other cytokines tested, including IL-10, IL-18, IFN-β, and TNF (Fig. S3, H--K). As expected, all APS-I patients had auto-Abs against IFN-α ([Fig. 1](#fig1){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}) and IFN-ω (not depicted). In addition, no IgA antibodies, a key element of mucosal immunity, directed against IL-17A, IL-17F, or IL-22 were detected in the plasma of 21 APS-I patients by classical ELISA (not depicted).

###### 

APS-I patients tested

  Patients   Gender   Age     Origin         *AIRE* genotype      Auto-Abs against   Mucocutaneous candidiasis phenotype                                                      
  ---------- -------- ------- -------------- -------------------- ------------------ ------------------------------------- -------- -------- ------ ------ ------ ----------- -------------------------------------
  APS-I 1    M        12 yr   Saudi Arabia   845insc/845insc      8,584              7,406                                 1,874    11,810   0.11   0.21   2.41   18 mo       Mouth, nails, esophagus
  APS-I 2    M        9 yr    Africa         c958del/c958del      1,070              1,264                                 23,963   13,661   0.03   2.16   2.41   6 yr        Nails, scalp, eyes
  APS-I 3    M        13 yr   Africa         c958del/c958del      6,467              4,824                                 28,271   13,265   0.03   2.61   2.51   --          Nails
  APS-I 4    F        26 yr   North Africa   ex6_8del/ex6_8del    10,836             828                                   1,765    761      0.02   0.11   0.26   16 yr       Nails, scalp
  APS-I 5    M        25 yr   North Africa   ex6_8del/ex6_8del    12,785             1,448                                 16,980   2,758    0.04   1.33   0.26   7 yr        Nails, scalp, digestive tract
  APS-I 6    F        10 yr   North Africa   ex6_8del/ex6_8del    3,705              1,998                                 16,742   5,691    --     1      1.09   1 mo        Mouth, eyes, vulva
  APS-I 7    M        10 yr   France         R257X/P539L          20,109             27,523                                25,409   18,446   2.29   1.95   2.83   2 mo        Mouth, esophagus, respiratory tract
  APS-I 8    F        21 yr   Ireland        964del13/964del13    14,169             192                                   1,645    5,914    0.02   0.13   0.21   3 yr        Mouth, scalp, skin
  APS-I 9    M        20 yr   Ireland        964del13/964del13    12,325             455                                   6,135    11,345   0.03   0.31   2.06   3 yr        Mouth, nails, perineum
  APS-I 10   F        29 yr   UK             964del13/964del13    9,371              734                                   15,140   615      0      0.11   0.03   4 yr        Mouth, esophagus, nails
  APS-I 11   F        36 yr   UK             964del13/964del13    12,078             148                                   4,439    102      0.01   0.15   0.16   Childhood   Mouth, esophagus, vagina
  APS-I 12   F        41 yr   UK             964del13/964del13    6,098              17,201                                24,837   9,749    0.16   0.47   0.64   4 yr        Mouth, nails, vagina, anus
  APS-I 13   F        18 yr   Ireland        964del13/964del13    13,379             367                                   548      2,708    0.02   0.1    0.18   Childhood   Skin, scalp
  APS-I 14   M        12 yr   Ireland        964del13/964del13    13,555             24,983                                17,131   22,225   0.36   0.35   1.06   Few weeks   Mouth, nails, scalp
  APS-I 15   M        18 yr   UK             964del13/964del13    16,906             28,484                                25,907   20,585   2.34   0.5    1.07   3 yr        Mouth, nails
  APS-I 16   M        18 yr   UK             964del13/964del13    15,473             28,262                                23,926   12,034   1.89   0.52   0.3    3 yr        Mouth, nails
  APS-I 17   M        13 yr   Ireland        964del13/964del13    8,086              805                                   23,917   14,558   0.02   0.64   0.91   5 yr        Mouth, nails
  APS-I 18   F        10 yr   UK             964del13/964del13    13,053             5,282                                 27,409   15,236   0.03   1.52   0.61   Few weeks   Mouth
  APS-I 19   M        6 yr    UK             964del13/964del13    13,797             13,588                                28,025   13,575   0.25   1.84   1.83   Birth       Mouth, perineum
  APS-I 20   M        17 yr   UK             964del13/964del13    11,946             11,272                                25,904   2,129    0.08   0.39   0.12   7 yr        Penis, perineum
  APS-I 21   M        9 yr    UK             964del13/964del13    13,127             752                                   12,048   18,039   0.08   0.44   1.11   2 yr        Esophagus, nails
  APS-I 22   F        52 yr   UK             964del13/c.769C\>T   8,012              955                                   22,886   4,502    ND     ND     ND     Childhood   Mouth
  APS-I 23   M        16 mo   Hungary        R257X/R257X          23,216             20,035                                4,531    21,012   0.55   0.08   2.31   --          None
  APS-I 24   M        18 yr   Hungary        R257X/C449fsX479     23,486             1,708                                 28,012   18,937   0.05   1.97   0.45   --          None
  APS-I 25   M        14 yr   Hungary        R257X/L323fsX373     23,923             2,025                                 9,169    5,259    0.06   0.15   0.18   --          None
  APS-I 26   F        21 yr   Hungary        R257X/R257X          23,120             12,359                                28,834   11,583   0.43   2.86   0.16   --          None
  APS-I 27   M        28 yr   Canada         964del13/964del13    21,225             737                                   7,576    5,047    0.02   0.09   0.04   3 yr        Mucosa, skin, nails, eyes, scalp
  APS-I 28   F        31 yr   Canada         964del13/964del13    22,324             26,214                                25,064   1,178    0.91   0.78   0.03   Birth       Mucosa, skin, nails, eyes, scalp
  APS-I 29   F        16 yr   Canada         delT253/R257X        24,099             2,268                                 13,563   15,899   0.08   0.79   0.14   2 yr        Nails
  APS-I 30   M        19 yr   Canada         delT253/R257X        21,442             153                                   448      1,264    0.03   0.04   0.24   3 yr        Mucosa, skin, nails
  APS-I 31   F        5 yr    Canada         964del13/964del13    22,798             26,120                                28,667   19,954   1.99   \>3    1.83   6 mo        Mucosa
  APS-I 32   F        31 yr   UK             964del13/964del13    14,718             2,155                                 27,222   14,358   ND     ND     ND     15 yr       Mouth, nails
  APS-I 33   F        7 yr    UK             964del13/964del13    15,332             25,648                                26,358   22,808   ND     ND     ND     4 yr        Mouth, nails, scalp

Sex; age; country of origin; *AIRE* genotype; levels of auto-Abs against IFN-α, IL-17A, IL-17F, and IL-22 measured by Luminex (FI values) or classical ELISA (OD values); and candidiasis phenotype are shown.

![**High titers of auto-Abs against IFN-α, IL-17A, IL-17F, and IL-22 in the plasma from patients with APS-I.** Anti--IFN-α, --IL-17A, --IL-17F, and --IL-22 circulating IgG titers were measured by multiplex particle-based flow cytometry in 33 samples from patients with APS-I and in 37 samples from healthy controls. FI is plotted on the y axis. Representative data for two experiments are shown.](JEM_20091983R_LW_Fig1){#fig1}

We also ran classical ELISA, with plasma samples diluted by a factor of five more than in the multiplex assays. 4 out of the 30 patients tested had high titers of IgG (OD \> 1) auto-Abs against IL-17A (P = 0.056), 10 patients had high titers of auto-Abs against IL-17F (P = 1.4 × 10^−7^), and 12 patients had high titers of auto-Abs against IL-22 (P = 1.23 × 10^−7^; [Fig. S1](http://www.jem.org/cgi/content/full/jem.20091983/DC1) and [Table I](#tbl1){ref-type="table"}). 17 patients had auto-Abs against at least one of these three cytokines, including 10 patients with auto-Abs against a single cytokine, 5 patients with auto-Abs against two cytokines, and 2 patients with auto-Abs against all three cytokines. No such auto-Abs were detected in the 37 healthy controls tested. This assay was not used to test patients with various autoimmune diseases. There were no detectable auto-Abs against TGF-β1, IL-6, IL-21, IL-23, or IL-26, or against IL-12 or IFN-γ in any of the APS-I patients ([Fig. S2, A--G](http://www.jem.org/cgi/content/full/jem.20091983/DC1)). Thus, in both ELISA and multiplex particle-based flow cytometry, the only auto-Abs detected in the 33 patients with APS-I tested were directed against IFN-α, IFN-ω, IL-17A, IL-17F, and IL-22 ([Fig. 1](#fig1){ref-type="fig"}, Fig. S1, and [Table I](#tbl1){ref-type="table"}). Moreover, all 33 patients with APS-I had auto-Abs against at least one out of three IL-17 cytokines (IL-17A, IL-17F, and IL-22). High titers of auto-Abs against all three of these cytokines were found in 22 patients.

We performed Western blotting to assess the specificity of these auto-Abs. Plasma samples from five patients with APS-I and auto-Abs against IL-17A, IL-17F, and/or IL-22, as detected by ELISA and multiplex particle-based flow cytometry, and from a healthy individual were tested for their ability to recognize rIL-17A, rIL-17F, and rIL-22 on Western blots. The three cytokines were clearly recognized by plasma samples from patients but not by the control plasma ([Fig. 2](#fig2){ref-type="fig"}). The plasma samples from patients did not recognize IL-23 in a control assay. Finally, we investigated whether the auto-Abs against IL-17A neutralized this cytokine in a simple biological assay. We incubated fibroblasts from a healthy control with up to 50 ng/ml rIL-17A in the presence of plasma from healthy individuals, or from a patient with APS-I and auto-Abs against IL-17, as detected by ELISA and Western blotting. We then measured the induction of IL-6 by ELISA on the supernatant. Strikingly, even strong dilutions of plasma samples from patients (up to 0.1%; not depicted) completely abolished fibroblastic cell responses to such high concentrations of rIL-17 ([Fig. 3](#fig3){ref-type="fig"}), whereas control plasma had no effect. Lower concentrations of IL-17A failed to induce IL-6, even in the presence of control plasma (unpublished data). The lack of robust bioassays precluded assessments of the possible neutralizing effects of auto-Abs against IL-17F and IL-22. Thus, all patients with APS-I tested had high titers of auto-Abs against IL-17A, IL-17F, and IL-22 in their plasma, and these auto-Abs were specific and neutralizing, at least in the patients tested. These data suggest that most patients with APS-I carry neutralizing auto-Abs against IL-17A, IL-17F, and IL-22.

![**Specific auto-Abs against IL-17A, IL-17F, and/or IL-22 in the plasma from patients with APS-I.** Western blot against rIL-17A, rIL-17F, rIL-22, and rIL-23 were performed using plasma from a healthy individual or from five patients with APS-I, diluted 1:500. Representative data for three experiments are shown. Dashed lines indicate that intervening lanes have been spliced out.](JEM_20091983_GS_Fig2){#fig2}

![**Neutralizing auto-Abs against IL-17A in the plasma from a patient with APS-I.** IL-6 production, after 48 h of stimulation with 50 ng/ml IL-17A, by control SV-40--transformed fibroblasts incubated with 10% plasma from two controls or from one patient (APS-I patient 7; means and errors bars from duplicates are shown). The data shown are representative of two experiments.](JEM_20091983R_GS_Fig3){#fig3}

APS-I patients may display auto-Abs against IL-17 cytokines as a result of impaired AIRE-dependent tolerance induction if the expression of the corresponding cytokine genes is normally controlled by AIRE in the thymus or in secondary lymphoid organs. Whatever the mechanism, these data suggest that impaired IL-17 immunity may account for CMC in patients with APS-I. In particular, these data are consistent with the impaired IL-17 immunity reported in other patients with known inborn errors of immunity predisposing to CMC (and other infectious diseases). Indeed, patients with low proportions (*IL12B*, *IL12RB1*) or a lack of (*STAT3*) IL-17--producing circulating T cells suffer from mild (*IL12B*, *IL12RB1*) or severe (*STAT3*) CMC, respectively. Patients with APS-I and auto-Abs against IL-17 cytokines do not suffer from severe staphylococcal disease, unlike STAT3-deficient patients ([@bib11]). Impaired IL-17 immunity probably contributes to staphylococcal disease in STAT3-deficient patients, as epithelial cells in the skin and lungs, the organs most frequently affected by staphylococcal infection in these patients, specifically rely on IL-17 stimulation for the induction of known antistaphylococcal target genes ([@bib30]). The lack of overt staphylococcal disease in most APS-I patients may result from residual IL-17 immunity, as observed to an even greater extent in patients with IL-12p40 and IL-12Rβ1 deficiencies who also control staphylococcal infections normally ([@bib9]). In any case, proof that human IL-17 cytokines play an essential role in immunity to *Candida* will require the identification of mutations specifically impairing IL-17 immunity in other patients with inherited, isolated CMC without APS-I ([@bib37]; [@bib14]). The recent observation that some patients with isolated CMC have smaller than normal proportions of IL-17--producing T cells and produce low levels of IL-17 suggests that this may be plausible (unpublished data; [@bib8]).

Various human diseases seem to be caused by the production of auto-Abs against cytokines. Patients with pulmonary alveolar proteinosis were shown to display auto-Abs against GM-CSF in 1999 ([@bib18]). Mutations in the GM-CSF receptor were subsequently found in other patients, establishing a causal relationship between impaired GM-CSF immunity and alveolar proteinosis ([@bib23]; [@bib38]). Patients with mycobacterial diseases and inherited IFN-γR1 deficiency were first reported in 1996 ([@bib9]). Autoimmune phenocopies, with auto-Abs against IFN-γ, were subsequently found in other patients ([@bib6]; [@bib16]; [@bib34]). We recently reported a patient with auto-Abs against IL-6 and staphylococcal disease ([@bib35]). There may be a causal relationship between auto-Abs against IL-6 and staphylococcal disease, as STAT3- and Tyk2-deficient patients suffer from staphylococcal disease and have a poor cellular response to IL-6 ([@bib28], [@bib29], [@bib30]). However, no germline mutation in the gene encoding IL-6 or its receptor has yet been reported in similar patients. This description of patients with auto-Abs against IL-17 cytokines is the fourth reported example of pathogenic auto-Abs against human cytokines. Other auto-Abs against cytokines not tested in this study, including some that would impair the development of IL-17--producing T cells, may also contribute to the development of CMC in APS-I patients.

MATERIALS AND METHODS
=====================

### Patients.

33 patients with APS-I (18 male and 15 female patients; [Table I](#tbl1){ref-type="table"} and [Table S1](http://www.jem.org/cgi/content/full/jem.20091983/DC1)), 103 patients with endocrine/autoimmune disorders, and 37 healthy controls (15 male and 22 female subjects) were enrolled in this study, with informed consent and approval obtained by the Necker Hospital and Medical School Institutional Review Board (IRB) and the Rockefeller University IRB.

### Plasma and serum samples.

Plasma and serum samples from the patients and controls were frozen at −20°C immediately after collection.

### ELISA.

ELISA was performed as previously described ([@bib35]). In brief, 96-well ELISA plates (MaxiSorp; Thermo Fisher Scientific) were coated by incubation overnight at 4°C with 2 µg/ml rIL-6, rIL-12p70, rIL-17A, rIL-17F, rIL-21, rIL-22, rIL-23, rIL-26 monomer, rIL-26 dimer, rTGF-β, and rIFN-γ (R&D Systems). Plates were then washed (PBS/Tween 0.005%), blocked by incubation with the same buffer supplemented with 5% nonfat milk powder, washed, and incubated with 1:500 dilutions of plasma samples from the patients or controls for 2 h at room temperature (or with specific mAbs as positive controls). Plates were thoroughly washed. Horseradish peroxidase (HRP)--conjugated Fc-specific IgG fractions from polyclonal goat antiserum against human IgG or IgA (Nordic Immunological Laboratories) were added to a final concentration of 2 µg/ml. Plates were incubated for 1 h at room temperature and washed. Substrate was added and OD was measured.

### Multiplex particle-based flow cytometry.

Recombinant human cytokines (rIL-1β, rIL-6, rIL-10, rIL-12p40, rIL-12p70, rIL-17A, rIL-17F, rIL-18, rIL-22, rIL-23, rIL-26 monomer, rIL-26 dimer, rIFN-α, rIFN-β, rIFN-γ, rTNF, and rGM-CSF; R&D Systems) were covalently coupled to carboxylated beads (Bio-Plex; Bio-Rad Laboratories). Beads were first activated with 1-ethyl-3-\[3-dimethylaminopropyl\]carbodiimide hydrochloride (Thermo Fisher Scientific) in the presence of *N*-hydroxysuccinimide (Thermo Fisher Scientific), according to the manufacturer's instructions, to form amine-reactive intermediates. The activated beads were incubated with the corresponding cytokines at a concentration of 20 µg/ml in the reaction mixture for 3 h at room temperature on a rotator. Beads were washed and stored in blocking buffer (10 mM PBS, 1% BSA, 0.05% NaN~3~). Cytokine-coupled beads were incubated with plasma or serum from patients for 1 h in 96-well filter plates (MultiScreenHTS; Millipore) at room temperature in the dark on a horizontal shaker. Fluids were aspirated with a vacuum manifold and beads were washed three times with 10 mM PBS/0.05% Tween 20. Beads were incubated for 30 min with a PE-labeled anti--human IgG-Fc antibody (Leinco/Biotrend), washed as described, and resuspended in 100 µl PBS/Tween. They were then analyzed on an analyzer (Bio-Plex) using Bio-Plex Manager 3.0 software (both from Bio-Rad Laboratories). Successful coupling of the cytokines to their respective bead sets was verified with specific mAbs.

### Western blotting.

We subjected 500 ng rIL-17A, rIL-17, rIL-22, rIL-23 (R&D Systems), or BSA to SDS-PAGE (10% acrylamide) under reducing conditions. The protein bands were electroblotted onto nitrocellulose membranes (iBlot Gel Transfer Stacks; Invitrogen). Membranes were blocked by incubation for 1 h at room temperature with PBS supplemented with 5% BSA and 0.05% Tween 20, and were washed and incubated overnight at 4°C with plasma samples from a patient or a control diluted 1:500 in PBS, 5% BSA, 0.01% Tween 20. The membranes were washed three times and incubated for 1 h at room temperature with HRP-coupled anti--human IgG and used at a final concentration of 0.67 µg/ml. The membranes were washed three times and developed for ECL (GE Healthcare).

### Neutralization assay.

SV-40--transformed control fibroblasts were plated in 24-well plates (60,000 fibroblasts/well) in 0.5 ml DMEM/10% FCS (Invitrogen). On the following day, cells were washed in 1× PBS (Invitrogen) and incubated with 10% plasma (from a control or a patient) in DMEM. They were left unstimulated or were stimulated with 50 ng/ml rIL-17A (R&D Systems). The supernatants were collected 24 and 48 h after stimulation, and IL-6 production was assessed by ELISA (Sanquin Mast Diagnostic) according to the manufacturer's instructions.

### Online supplemental material.

Fig. S1 shows anti--IL-17A, --IL-17F, and --IL-22 IgG auto-Abs measured by ELISA in plasma from APS-I patients and controls. Fig. S2 shows anti--TGF-β1, --IL-6, --IL-21, --IL-23, --IL-12, --IFN-γ, and --IL-26 IgG auto-Abs measured by ELISA in plasma from controls and APS-I patients. Fig. S3 shows anti--IL-1β, --IL-6, --IL-23, --IL-26, --IL-12, --IFN-γ, --GM-CSF, --IFN-β, --IL-10, --IL-18, and -TNF IgG auto-Abs measured by multiplex particle-based flow cytometry in plasma from healthy controls and APS-I patients. Fig. S4 shows anti--IFN-α, --IL-17A, --IL-17F, and --IL-22 IgG auto-Abs in 100 patients suffering from autoimmune and/or endocrine disorders. Table S1 shows the autoimmune/endocrine phenotypes and treatments of each APS-I patient tested. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20091983/DC1>.
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